Comparison of nitrimidazone and metronidazone in the treatment of trichomonal vaginitis

J. S. McCANN, J. D. H. MAHONY, AND J. R. W. HARRIS
Royal Victoria Hospital, Belfast, Northern Ireland

Until the introduction of metronidazole, the treatment of trichomonal vaginitis presented a considerable therapeutic problem. Local treatment was commonly followed by recurrence of the condition, doubtless partly because vaginal treatment alone failed to eliminate all foci of infection. Moreover, it became apparent that trichomonal infection was also often present in the male (Watt and Jennison, 1960; Catterall and Nicol, 1960) and no effective treatment in the male was available. The introduction of metronidazole by Durel, Roiron, Siboulet, and Borel (1959), however, resulted in a dramatic change, with a high percentage of both men and women responding rapidly to treatment with the drug (Rodin, King, Nicol, and Barrow, 1960). That metronidazole was not effective in all cases, however, soon became apparent (Rodin, King, Nicol, and Barrow, 1960; Willcox, 1960), and the search continued for a compound that would give even more effective results. In 1969, a new synthetic compound derived from nitro-imidazole, nitrimidazone, was introduced for the treatment of trichomoniasis (Emanuelli and de Carneri, 1969). It was claimed that the trichomonicidal activity in blood serum samples taken from humans treated orally with 250 mg. doses of the new product was stronger and more rapid than with metronidazole (de Carneri, Cantone, Emanuelli, Giraldi, Logemann, Meinardi, Monti, Nannini, Tosilini, and Vita, 1969). Moreover, whereas the metabolites of metronidazole were inactive, those of nitrimidazone were stated to retain part of their activity. Therapeutic action was thus provided not only by the drug itself but also by its principal metabolites (de Carneri and others, 1969).

Various claims for the therapeutic effectiveness of nitrimidazone have been made since its introduction. Emanuelli and de Carneri (1969) reported an overall cure rate of 92.5 per cent. using different dosage regimens. With a dosage of 250 mg. twice daily for 6 days, Cohen (1971) stated that 62 of 63 women completing surveillance were cured. Moffett, McGill, Schofield, and Masterton (1971), on the other hand, had an overall minimum failure rate of 16 per cent., 6-6 per cent. being regarded as ‘primary’ failures, while Evans and Catterall (1971) found the drug successful in only 68 per cent. of 57 patients.

The present investigation was carried out in the Department of Venereology, at the Royal Victoria Hospital, Belfast, to assess and compare the effectiveness of treatment with nitrimidazone and metronidazole.

Material and methods

100 female patients (Tables I and II) were treated with either nitrimidazone or metronidazole. Apart from three patients in whom the infection was resistant to the routine dosage of nitrimidazone and who were then given metronidazole in routine dosage, the patients were chosen at random for the treatment given, 48 receiving nitrimidazone and 52 metronidazole. The routine dosage was 250 mg. nitrimidazone twice daily for 6 days or 200 mg. metronidazole three times a day for 7 days.

**TABLE I Age distribution (range 15 to 56 yrs)**

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>15-16</td>
<td>5</td>
</tr>
<tr>
<td>17-20</td>
<td>24</td>
</tr>
<tr>
<td>21-25</td>
<td>20</td>
</tr>
<tr>
<td>26-30</td>
<td>23</td>
</tr>
<tr>
<td>31-40</td>
<td>19</td>
</tr>
<tr>
<td>41-50</td>
<td>6</td>
</tr>
<tr>
<td>50 and over</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
</tr>
</tbody>
</table>

**TABLE II Marital status**

<table>
<thead>
<tr>
<th>Status</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Married</td>
<td>32</td>
</tr>
<tr>
<td>Single</td>
<td>55</td>
</tr>
<tr>
<td>Separated</td>
<td>11</td>
</tr>
<tr>
<td>Divorced</td>
<td>1</td>
</tr>
<tr>
<td>Widowed</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
</tr>
</tbody>
</table>
Each patient was examined clinically; diagnosis was based on the finding of the parasite by microscopy of the vaginal secretion, and on culture in Feinberg-Whittington medium. The patients were seen at frequent intervals during the first 2 weeks of treatment, and thereafter at weekly and then monthly intervals for 3 months or longer. Wet preparations from the vaginal secretions were examined microscopically at each visit, and cultures were taken as at the first examination.

Smears and culture for gonococci and Candida albicans were made at the same time, and serological investigations for syphilis were carried out as a routine; 74 additional sexually transmitted infections were found (Table III).

**Table III Numbers of patients suffering from other venereal diseases**

<table>
<thead>
<tr>
<th>Condition</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gonorrhoea</td>
<td>32</td>
</tr>
<tr>
<td>Syphilis</td>
<td>5</td>
</tr>
<tr>
<td>Warts</td>
<td>11</td>
</tr>
<tr>
<td>Candidiasis</td>
<td>23</td>
</tr>
<tr>
<td>Scabies</td>
<td>3</td>
</tr>
</tbody>
</table>

*1 Congenital
1 Early latent
1 Late latent
2 Primary

When possible the male consorts were treated simultaneously.

**Results**

The results of treatment are shown in Table IV.

**Table IV Results of treatment with nitrimidazole and metronidazole**

<table>
<thead>
<tr>
<th>Result</th>
<th>Nitrimidazole</th>
<th>Metronidazole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cured</td>
<td>23</td>
<td>40</td>
</tr>
<tr>
<td>Primary failure</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Secondary failure</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><em>Default cure?</em></td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Immediate failure</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>48</td>
<td>52</td>
</tr>
</tbody>
</table>

*Patients who defaulted within 3 to 4 weeks but were trichomonas negative at the time of default.

Excluding the two immediate defaulters, 36 (approximately 78 per cent.) of the 46 patients treated with nitrimidazole had negative tests for the full period of follow-up or at the time of default. Ten (approximately 22 per cent.) were either primary (9) or secondary (1) failures. Of the nine primary failures, three were then treated with the routine dosage of metronidazole which also proved ineffective, but they subsequently responded to an increased dosage of metronidazole (400 mg. three times a day for 7 days).

The corresponding figures for metronidazole (excluding the three defaulters) were 44 (approximately 90 per cent.) cured without later recurrences, and five (approximately 10 per cent.) primary failures. These five failures included the three who had failed to respond to nitrimidazole, and of the other two one responded subsequently to nitrimidazole 1 g. followed by 500 mg. twice daily for 6 days. The second patient, who was given the same dosage, defaulted before the full period of follow-up, but gave a negative result at the time of default.

Six patients who failed to respond to both nitrimidazole and metronidazole were of special interest because they posed difficult problems regarding further management. The treatment and response were briefly as follows:

**Case 34/70**

This patient failed to respond to routine courses of both nitrimidazole and metronidazole. Subsequently a further course of nitrimidazole was given as 1 g. stat. followed by 250 mg. three times a day for 7 days. After a period of negative tests, the *Trichomonas* was again isolated and the patient was treated with a combination of nitrimidazole and metronidazole, one tablet of each three times daily for 7 days, plus Pimafucin pessaries. She defaulted 4 weeks later but was trichomonas-negative at the time of default.

**Case 180/70**

Routine courses of both nitrimidazole and metronidazole were unsuccessful. Subsequently she was given a further routine course of metronidazole tablets vaginally (1 twice daily for 10 days): this also failed. She was then given a course of S.V.C. pessaries (1 twice daily for 18 days) and the trichomonads disappeared. She was still trichomonas negative when discharged from observation at the end of 5 months.

**Case 70/88**

This patient failed to respond to nitrimidazole, and also to nitrimidazole and metronidazole, 1 tablet of each three times a day for 7 days, plus Pimafucin pessaries. She responded finally to metronidazole tablets 400 mg. three times a day for 7 days plus 1 tablet vaginally twice daily for 14 days. She was still trichomonas-negative at the end of 2 months.

**Case 748/70**

Repeated courses of metronidazole and pentontrane pessaries given elsewhere had been unsuccessful. She failed to respond to nitrimidazole tablets 250 mg. three times a day for 7 days, followed by a combined course of nitrimidazole and metronidazole (as in the previous case), and then to metronidazole tablets 400 mg. three times a day for 7 days plus Pimafucin pessaries.

**Case 384/71**

This patient was not helped by routine courses of metronidazole and nitrimidazole, followed by metronidazole 400 mg
three times daily for 7 days and 1 tablet vaginally twice daily. This patient had a low I.Q. and may have been re-infected.

**Case 303/71**

This patient did not respond to repeated courses of both nitrimidazole and metronidazole separately and in combination and in varying dosages. She eventually defaulted.

In Cases 180/70, 70/68, and 746/70, the contacts were also treated. Case 303/71 was pregnant and living in a home for unmarried mothers, so that re-infection was unlikely. The baby was normal.

Case 746/70 complained of sleeplessness and anorexia whilst taking nitrimidazole; otherwise no toxic reactions were observed with either preparation.

**Discussion**

As other workers have noted, assessment of the final results is not easy, as there is always the possibility of re-infection in cases of recurrence, and no matter how carefully out-patients are chosen for a trial, there is no guarantee that the tablets will be taken as directed and the course completed. As mentioned earlier, as many male consorts as possible were treated with one or other drug, and among the cases of treatment failure no fewer than eleven consorts had received treatment. In all, 47 male consorts were treated, a figure rather lower than in the series reported by Cohen (1971), but higher than in that of Moffett and others (1971).

In our series, nitrimidazole did not appear to give such satisfactory results as metronidazole in the dosage recommended, though our results were better than those reported by Evans and Catterall (1971), and would appear to be more in line with those of Moffett and others (1971). Like Cohen (1971), we also found the clinical response to nitrimidazole to be rather slower than that to metronidazole.

The response to further treatment with both drugs was disappointing in cases of initial failure. Emanuelli and de Carneri (1969) stated that nitrimidazole was also active topically, and reported a cure rate of 95.5 per cent. after the use of 250 mg. vaginal suppositories daily for 6 to 10 days. It is possible that some infections which resisted routine methods of treatment might have responded to this form of therapy. One of our patients (76/68) did finally respond to metronidazole tablets used both orally and as a pessary.

**Current investigation**

An investigation with nitrimidazole is now being carried out, giving a 2-day course of treatment consisting of five 250-mg. tablets as a first dose in the morning, followed by three 250-mg. tablets at night, the same dosage being repeated on the second day. Forty patients have been treated to date; seven defaulted immediately, leaving 33 patients for assessment.

Two treatment methods were adopted:

1. The first dose of five tablets was administered in the clinic, and the second dose of three tablets was given to the patient with instructions to take them at bedtime. The patient was seen and reassessed the following morning and the same regimen was followed for the second day.

2. If the patient was unable to attend on the second day, the first dose was taken in the clinic as before, and the remainder of the tablets were given with explicit instructions how they were to be taken.

25 patients were treated by the first method, and reassessment and follow-up were carried out as in the earlier investigation. Using the same classification as before, the results are given in Table V.

<table>
<thead>
<tr>
<th><strong>TABLE V</strong> Results in forty patients in current trial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Result</strong></td>
</tr>
<tr>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>Cured</td>
</tr>
<tr>
<td>Primary failure</td>
</tr>
<tr>
<td>Secondary failure</td>
</tr>
<tr>
<td>*Default cure?</td>
</tr>
<tr>
<td>Immediate default</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

*see Table IV

The patient classed as a secondary failure was probably re-infected by her husband. She was trichomonas-negative after the first day's treatment but positive a few weeks later, and denied extramarital exposure. She was given a second course of treatment similar to the first and her husband, who had not been treated on the first occasion, was now treated similarly. She again became trichomonas-negative after the first day and remained so until she defaulted 2 months later.

Of the 25 patients in Group 1 (those seen on the second morning), all were already trichomonas-negative after the first day's dosage. Of those in Group 2, all were trichomonas-negative at the follow-up examinations. In spite of the negative findings in the 25 patients after the first day's treatment, a second day's treatment was given.

We have not yet attempted to give a one-day treatment only, but it is possible that this or indeed a single-dosage schedule may prove to be effective in the treatment of trichomoniasis.

Csonka (1971), using a single dosage schedule of 2 g. metronidazole (Flagyl) in 36 cases, had a cure...
rate of only 82 per cent., but the results in our present
series would appear to be more impressive.
Apart from a few patients who complained of
slight nausea or abdominal discomfort no unpleasant
side-effects were noted.

Summary
Of 100 women with trichomoniasis, 48 were treated
with nitrimidazone and 52 with metronidazole, the
patients being chosen primarily on a random basis.
Diagnosis was made by microscopy and culture in
Feinberg-Whittington medium. The patients were
followed-up for at least 3 months where possible.
The dosage of nitrimidazone was 250 mg. twice daily
for 6 days and of metronidazone 200 mg. three times
daily for 7 days. 78 per cent. of the patients treated
with nitrimidazone were either cured or had negative
tests at the time of default; the corresponding figure
for metronidazone was 90 per cent. 47 of their male
consorts were also treated. Several patients failed to
respond to both preparations and various combina-
tions and dosages were tried with indifferent success.
A current trial, employing a 2-day course with a
dosage of five 250-mg. tablets of nitrimidazone in the
morning and three 250-mg. tablets at night, is now
being carried out, so far with highly encouraging
results.

Our thanks are due to Carlo Erba (U.K.) Limited for
supplies of nitrimidazone (Naxogin) and for their advice,
interest, and help throughout the trial, and to our own
clinic laboratory staff for their co-operation and help in
the investigation.

References
1, 1177
Csonka, G. W. (1971) Ibid., 47, 456

de Carneri, I., Cantine, A., Emanuelli, A., Giraldi,
P. N., Logemann, W., Meinarbi, G., Monti, G.,
International Congress of Chemotherapy, Tokyo,
August, 1969
Durel, P., Roiron, V., Siboulet, A., and Borel, L. J.
(1959) C. R. Soc. franç. Gynec., 28, 36
Congress of Chemotherapy, Tokyo, August, 1969,
and personal communication
4, 146
Moffett, M., McGilli, M. L., Schofield, C. B. S., and
Rodin, P., King, A. J., Nicol, C. S., and Barrow, J.
(1960) Ibid., 36, 147
Watt, L., and Jennison, R. F. (1960) Ibid., 36, 163
Willcox, R. R. (1960) Ibid., 36, 175

Comparaison de la nitrimidazone et du
métronidazole dans le traitement de la vaginite
à trichomonas

SOMMAIRE
Sur 100 femmes atteintes de trichomonase, choisies en
principe par randomisation, 48 furent traitées par la
nitrimidazone, 52 par le métronidazole. Le diagnostic
était fait par l'examen sur lâne et par la culture sur
milieu de Feinberg-Whittington. Les malades furent
suivies pendant au moins trois mois chaque fois que ceci
fut possible. La nitrimidazone fut donnée à la dose de
250 mg, 2 fois par jour pendant 6 jours et le métroni-
dazole à 200 mg. 3 fois par jour pendant 7 jours. 78
pour cent des malades traitées par la nitrimidazone furent
soit guéries soit négatives aux épreuves à la fin de l'observa-
tion ; pour le métronidazole, le chiffre fut de 90 pour cent.
47 des partenaires masculins de ces malades furent
egalement traités. Quelques malades ne répondirent à
aucune des deux préparations et différentes associations
ou posologies furent essayées sans que l'on puisse attribuer
la guérison à l'une plutôt qu'à l'autre.

Un essai est actuellement en cours, utilisant un traite-
ment de 2 jours à la posologie de cinq comprimés de
250 mg de nitrimidazone le matin et de trois comprimés
de 250 mg le soir ; jusqu'ici, les résultats sont très en-
courageants.